Thiago A Patente, Julian van Duijvenvoorde, Graham A Heieis, Eline C Brombacher, Leonard R Pelgrom, Joost Lambooij, Anna Zawistowska-Deniziak, Martina Erbì, Frank Otto, Arifa Ozir-Fazalalikhan, Sara Barnhoorn, José J Fernández, Johan van der Reijden, Alwin J van der Ham, Lukas J A C Hawinkels, Bruno A Guigas, José A M Barbuto, Rick M Maizels, Bart Everts
Intestinal dendritic cells (DCs) play a central role in maintaining gut tolerance through priming of peripheral regulatory T cells (pTreg cells). DC tolerogenicity has been linked to catabolic metabolism, but the role of AMP-activated kinase (AMPK), a key regulator of catabolic metabolism, in regulating intestinal tolerance remains unclear. We found high AMPK activation in intestinal DCs, and loss of AMPKα1 in CD11c-expressing cells (CD11cΔAMPKα1) led to reduced frequencies of intestinal RALDH+ CD103+ cDC2s. This was associated with reduced pTreg cell induction and consequently increased type 2 immunity in models of intestinal helminth infection. Correspondingly, CD103+ cDC2s from helminth-infected CD11cΔAMPKα1 mice failed to prime Treg cells ex vivo. Similarly, Treg cell induction by AMPK-deficient human retinoic acid (RA)-induced tolerogenic CD103+ DCs was compromised. Mechanistically, AMPK underpinned RA-driven tolerogenicity by promoting RALDH activity and TGF-β secretion in a FoxO3-dependent manner, independent from metabolic reprogramming. Our findings identify AMPK as a key regulator of intestinal DC-mediated tolerance and as a therapeutic target to counter intestinal inflammatory disease.